Myriad Asset Management’s Starling Oncology Warrant STLNW Stock Holding History

Myriad Asset Management’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,500	Closed	-$24K	–	141
2020 Q4	$24K	Hold	12,500	–	–	﹤0.01%	81
2020 Q3	$21K	Buy	+12,500	New	+$20.5K	﹤0.01%	57

Other funds holding STLNW

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return

JP Morgan Chase

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Myriad Asset Management's STLNW Position: Q1 2021 in Review

Myriad Asset Management sold out of Starling Oncology Warrant (STLNW) in Q1 2021, closing a stake of 12,500 shares — an estimated $24K sold.

Myriad Asset Management first reported a position in STLNW in Q3 2020 and held it in 2 quarters. The position peaked at $24K in Q4 2020. 29 funds tracked by Wall St. Rank hold STLNW as of Q1 2021.

Myriad Asset Management reported no remaining Starling Oncology Warrant position as of Q1 2021 after selling out during the quarter.
Myriad Asset Management sold 12,500 Starling Oncology Warrant shares in Q1 2021, an estimated $24K.
Myriad Asset Management first reported a position in Starling Oncology Warrant in Q3 2020 and held it in 2 quarters.
Myriad Asset Management's Starling Oncology Warrant position peaked at $24K in Q4 2020.
29 funds tracked by Wall St. Rank held Starling Oncology Warrant as of Q1 2021.

Based on Myriad Asset Management's 13F filing for Q1 2021, filed 14 May 2021.